Replies to post #241240 on Biotech Values

[DewDiligence]

Thanks. Yet another question: Why are the incentives for the prescribers materially different in the two indications in question?

I get the advantage of Myfembree's FDC formulation. Wonder how ABBV will counter-detail on that aspect.